These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22908995)

  • 21. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
    Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
    Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
    Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy.
    Armstrong PC; Dhanji AR; Tucker AT; Mitchell JA; Warner TD
    J Thromb Haemost; 2010 Mar; 8(3):613-5. PubMed ID: 19995405
    [No Abstract]   [Full Text] [Related]  

  • 24. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
    Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
    J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
    Clarke RJ; Mayo G; Price P; FitzGerald GA
    N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease.
    Santos MT; Valles J; Lago A; Tembl J; Sánchez E; Moscardo A; Cosin J
    J Thromb Haemost; 2008 Apr; 6(4):615-21. PubMed ID: 18221358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets: evidence for the requirement of a methyl transfer reaction in platelet activation.
    Lecompte T; Randon J; Chignard M; Vargaftig BB; Dray F
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():441-7. PubMed ID: 6221560
    [No Abstract]   [Full Text] [Related]  

  • 29. Metabolomic investigation of the anti-platelet aggregation activity of ginsenoside Rk₁ reveals attenuated 12-HETE production.
    Ju HK; Lee JG; Park MK; Park SJ; Lee CH; Park JH; Kwon SW
    J Proteome Res; 2012 Oct; 11(10):4939-46. PubMed ID: 22873173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Turgeon J; Palisaitis DA; Diodati JG
    Eur Heart J; 2007 Jul; 28(14):1702-8. PubMed ID: 17569678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of thromboxane A2 and aorta-contracting activity from platelets stimulated with modified C-reactive protein.
    Simpson RM; Prancan A; Izzi JM; Fiedel BA
    Immunology; 1982 Sep; 47(1):193-202. PubMed ID: 7118160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Collection, preparation and storage of human plasma for radioimmunologic determination of thromboxane B2].
    Nell A; Kment G; Matejka M; Porteder H; Peskar BA; Sinzinger H
    Wien Klin Wochenschr; 1988 Nov; 100(21):700-6. PubMed ID: 3242305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terms and conditions: semantic complexity and aspirin resistance.
    Hennekens CH; Schror K; Weisman S; FitzGerald GA
    Circulation; 2004 Sep; 110(12):1706-8. PubMed ID: 15381661
    [No Abstract]   [Full Text] [Related]  

  • 35. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity.
    Park WH; Kim KS; Kim KH; Kim DS; Kim CH
    Int Immunopharmacol; 2003 Jul; 3(7):971-8. PubMed ID: 12810354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.
    Vainio M; Riutta A; Koivisto AM; Mäenpää J
    Acta Obstet Gynecol Scand; 2004 Dec; 83(12):1119-23. PubMed ID: 15548142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease.
    Kidson-Gerber G; Weaver J; Gemmell R; Prasan AM; Chong BH
    Heart Lung Circ; 2010 Apr; 19(4):234-42. PubMed ID: 20144559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of aspirin's effect on platelet function early after coronary artery bypass grafting.
    Bednar F; Tencer T; Plasil P; Paluch Z; Sadilkova L; Prucha M; Kopa M
    J Cardiothorac Vasc Anesth; 2012 Aug; 26(4):575-80. PubMed ID: 22281116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.